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CXCR4-expressing Mist1 progenitors in the gastric antrum
contribute to gastric cancer development
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ABSTRACT
Mist1 was recently shown to identify a discrete population of stem cells within
the isthmus of the oxyntic gland within the gastric corpus. Chief cells at the base of
the gastric corpus also express Mist1. The relevance of Mist1 expression as a marker
of specific cell populations within the antral glands of the distal stomach, however,
is unknown. Using Mist1-CreERT mice, we revealed that Mist1+ antral cells, distinct
from the Mist1+ population in the corpus, comprise long-lived progenitors that reside
within the antral isthmus above Lgr5+ or CCK2R+ cells. Mist1+ antral progenitors
can serve as an origin of antral tumors induced by loss of Apc or MNU treatment.
Mist1+ antral progenitors, as well as other antral stem/progenitor population, express
Cxcr4, and are located in close proximity to Cxcl12 (the Cxcr4 ligand)-expressing
endothelium. During antral carcinogenesis, there is an expansion of Cxcr4+ epithelial
cells as well as the Cxcl12+ perivascular niche. Deletion of Cxcl12 in endothelial cells
or pharmacological blockade of Cxcr4 inhibits antral tumor growth. Cxcl12/Cxcr4
signaling may be a potential therapeutic target.

INTRODUCTION

contains multiple histological subtypes with distinct
molecular signatures, but dominant oncogenic mutations
are generally less frequent in gastric cancers than in
other gastrointestinal cancers [3], limiting opportunities
for targeted therapy in the disease. Cancer growth is

Gastric cancer is one of the leading causes of cancer
death worldwide, and the prognosis for patients with
advanced disease remains poor [1, 2]. Gastric cancer
www.impactjournals.com/oncotarget
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recombination in the antrum of Mist1-CreERT mice, and
that Mist1 antral lineages appeared to contribute to tumor
development [17]. To clarify Mist1 expression in the
stomach in more detail, we looked at an entire longitudinal
section of Mist1-CreERT; R26-TdTomato mice 5 days
after tamoxifen (TAM) induction (Figure 1A). As reported
previously [9], there are abundant TdTomato+ chief cells
at the corpus gland base, while there are TdTomato+ stem
cells above GSII+ mucous neck region, some of which
start to lineage trace from the corpus isthmus. In addition,
we observed scattered, but solid TdTomato expression
within the antral isthmus where stem/progenitors are
thought to reside, in contrast to previous reports [16].
These cells reside adjacent to GSII-expressing deep antral
mucous cells, but most of them do not overlap. In addition,
these TdTomato+ cells are negative for other differentiated
cell markers found in this region, including Dclk1,
somatostatin, and gastrin (Supplementary Figure 1A). In
situ hybridization confirmed Mist1 mRNA expression in
cells at this position (Supplementary Figure 1B–1C), while
Mist1 protein was not detected by immunohistochemical
staining (not shown). We performed RT-PCR using mRNA
extracted from different parts of the stomach including
forestomach, corpus, and antrum, and confirmed that Mist1
is expressed in the antrum, at a lower level compared to the
corpus, but a higher level compared to the forestomach,
where no TdTomato+ cells are seen (Supplementary Figure
1C, 1D). A gastrin receptor gene Cckbr, which is expressed
in differentiated cells in the corpus and stem cells in the
antrum, is also expressed in these parts similar to Mist1.
Lgr5 expression is equivalent between corpus and antrum,
as reported previously [18]. Thus, Mist1 expression level
well correlates with recombination rate in each part of the
stomach of Mist1-CreERT mice.
We next performed a detailed time course of lineage
tracing in Mist1-CreERT; R26-mTmG mice. The Mist1CreERT; R26-mTmG mice showed isolated recombined
GFP+ cells in the lower third of antral glands at 1 day after
TAM induction (Figure 1D–1E). Mist1+ cells were present
at average of 1-2 cells/gland, ranging from position 1 to
7 with a peak at position +5. After TAM induction, the
Mist1+ lineage expanded gradually with a doubling time
of ~4 days, and entire antral glands were labeled within
30 days (Figure 1D–1E). Similar lineage tracing pattern
in antral glands was also observed in Mist1-CreERT;
R26-LacZ and Mist1-CreERT; R26-TdTomato mice
(Supplemantary Figure 1E–1F). Lineage tracing in these
mice persisted beyond 18 months, and the Mist1 lineage
contained all cell types including TFF1+ surface pit cells,
gastrin+ G cells, somatostatin+ D cells, and Dclk1+ tuft
cells. (Figure 1H). The frequency of lineage tracing was
consistent throughout the observation period, depending
on the reporter strain used (Figure 1G). We did not observe
any tamoxifen-induced epithelial injury in the antrum
during the time course, as reported previously [19].
Lineage tracing during in vitro organoid culture supported

influenced greatly by interactions between cancer stem
cells and the tumor microenvironment, which has emerged
as a promising therapeutic target [4, 5]. Cancer stem cells
are believed to arise from normal stem or progenitor cells
[6]. Stem cells are defined by the properties of self-renewal
and multi-potency, or the ability to give rise to more than
one lineage, which are modulated to some extent by the
surrounding microenvironment or niche [7, 8].
The mouse stomach is comprised of three major
parts, forestomach, corpus, and antrum. Forestomach
consists of squamous epithelium and thus is in many
aspects more similar to esophageal epithelium. The
proximal part corpus and distal part antrum have
columnar epithelium and are collectively referred to the
glandular stomach. We recently showed that relatively
quiescent Mist1+ gastric corpus stem cells located in the
isthmus, where the corpus gland narrows near the upper
third position of glands, can serve as the cellular origin
of all epithelial lineages, as well as gastric cancer. In
the corpus, Mist1+ stem cells are regulated by Cxcl12+
endothelial cells and Cxcr4+ innate lymphoid cells (ILCs),
and the Cxcl12/Cxcr4 niche is required for progression
to diffuse-type gastric cancer [9]. During inflammation,
the Cxcl12/Cxcr4 niche expands and supports cancer
cell growth by paracrine release of growth factors such
as Wnt5a. However, the gastric corpus and antrum are
two different organs, in terms of not only anatomical and
functional differences but also their stem cell biology and
contribution to carcinogenesis. Moreover, intestinal-type
gastric cancer is typically more common in Helicobacter
pylori-related human gastric cancers than diffuse-type.
Therefore, the contribution of Cxcl12/Cxcr4 in antral stem
cells and other form of gastric cancer has not been fully
elucidated.
In the gastric antrum, several stem/progenitor cell
markers have been identified such as CCK2R, Sox2, eR1,
Villin, Axin2, and Lgr5 [10–15]. Lgr5+ cells are present at
the base of antral glands, whereas other stem/protenitor
cells reside within the antral isthmus, where gland
narrows just above Lgr5+ cells. Although Wnt and Notch
signaling have been suggested as important modulators
of gastrointestinal stem cells, other critical niche signals
that regulate antral stem cells, and that might contribute to
the development of cancer, have not been fully explored.
Here, we identify Mist1 expression in antral isthmus
progenitors, and define their contribution to the antral
lineages and to gastric cancer. Finally, we demonstrate a
role for Cxcl12/Cxcr4 signaling in antral tumorigenesis.

RESULTS
Mist1 is expressed in long-lived isthmus
progenitors in the antrum
Although Mist1 expression has been reported in
the gastric corpus [16], we recently found abundant Cre
www.impactjournals.com/oncotarget
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an expansion of the Mist1+ lineage (Figure 1I). Together,
these results suggest that Mist1-expressing antral cells
contain long-lived, multipotent progenitors in the isthmus.

mice [11, 12]. One day after TAM induction, Mist1+
cells were distinct from Cckbr-GFP+ and Sox2-GFP+
cells based on immunofluorescent and FACS analysis
(Figure 2H–2I, Supplementary Figure 2B–2C).
Immunohistochemistry confirmed that CCK2R+ cells were
located at the +4 position, just below Mist1+ cells (Figure
2J–2K). Axin2 protein, a recently reported antral stem cell
marker, is expressed in the isthmus, but there is no overlap
with Mist1+ cells (Supplementary Figure 2D). Mist1+ cells
were able to generate Sox2+ and CCK2R+ cells and indeed
all epithelial lineages within the antral gland, suggesting
Mist1 also labels bona fide antral stem cells, although
interconversion between these various states cannot be
excluded (Figure 2H, 2J–2L, Supplementary Figure 2C).

Mist1+ cells take up BrdU more rapidly than
Lgr5+ cells in the antrum
Given that Lgr5 expression has also been associated
in the antrum with long-lived, self-renewing stem cells [10],
we examined possible overlap between Mist1 and Lgr5
using Mist1-CreERT; Lgr5-DTR-GFP; R26-TdTomato
mice. Although Mist1+ cells and Lgr5+ cells are often
located in close proximity, Mist1+ cells were again located
slightly higher up in the antral glands, and the vast majority
(e.g. > 95%) of Mist1+ cells were found to be Lgr5-negative
by microscopic and FACS analysis (Figure 2A–2B). We
sorted Lgr5-high and Lgr5-low expressing cells separately,
and confirmed that Mist1 mRNA is expressed in Lgr5low cells, but not in Lgr5-high cells (Figure 2C). We
then ablated Lgr5+ cells by administration of diphtheria
toxin (DT), and found that lineage tracing of Mist1+
cells still occurred with unchanged kinetics (Figure 2D).
Furthermore, the Lgr5+ cells reappeared by 30 days within
the Mist1+ lineage, indicating that Mist1+ stem cells can
give rise to Lgr5+ cells. Taken together, Mist1+ antral stem
cells are mostly distinct from Lgr5+ cells.
To further analyze the differences between
Mist1+ and Lgr5+ antral cells, we administered
bromodeoxyuridine (BrdU) to Lgr5-EGFP-IRES-CreERT
mice and Mist1-CreERT; R26-mTmG mice continuously
through their drinking water. Lgr5-high cells at the
base of glands (positions +1 to +3) failed to label with
BrdU in the first few weeks, while Lgr5-low cells in
the isthmus occasionally took up BrdU and then such
labeling expanded bi-directionally (Figure 2E). However,
it required more than 4 weeks to label all basal Lgr5+ cells
with continuous BrdU administration, suggesting that many
of these cells are either quiescent or post-mitotic. Indeed,
using a FucciG1 transgenic mouse line where cells in G1
cell cycle state turns into red and cells in post-mitotic cells
show bright red signal due to accumulation of fluorescent
protein after cell cycle exit [20], we realized that most
of Lgr5-high cells in the antrum of Lgr5-EGFP-IRESCreERT; FucciG1 mice display bright red nuclei thus they
are likely post-mitotic (Supplementary Figure 2A).
In contrast, while Mist1+ cells did not take up BrdU
immediately, consistent with their doubling time of 4 days,
they could be uniformly labeled with BrdU within two
weeks (Figure 2F, 2G). Thus, these data suggest marked
differences in cellular kinetics between Mist1+ and Lgr5+
cells, with the Mist1+ cells labeling with BrdU well before
Lgr5-high cells.
To investigate possible overlap between Mist1+
cells and Sox2+ or CCK2R+ antral stem cells, we
generated Mist1-CreERT; Sox2-EGFP; R26-TdTomato
mice and Mist1-CreERT; Cckbr-EGFP; R26-TdTomato
www.impactjournals.com/oncotarget

Antral Mist1+ cells serve as a cellular origin of
cancer
Given that Mist1+ antral cells function as stem cells
in the normal stomach, we investigated whether Mist1+
stem cells could be a cell-of-origin for antral gastric
metaplasia and cancer. We generated Mist1-CreERT;
LSL-KrasG12D mice, which were previously shown to
rapidly develop gastric metaplasia of the corpus [9]. At
day 14 after induction of mutant Kras in Mist1+ cells,
we found rapid expansion from the antral gland base of
mucous-producing cells that were Alcian Blue+, and which
populated entire glands in a gland-by-gland fashion (Figure
3A). The expansion of Kras-activated, p-ERK+ cells was
accompanied by an increase in CD44 and GSII expression,
a marker of gastric preneoplasia [13] (Figure 3B–3C).
Thus, Kras activation in Mist1+ antral stem cells causes
antral hyperplasia with expansion of preneoplastic cells.
We next treated the Mist1-CreERT; R26-mTmG
mice with the chemical carcinogen, N-nitroso-Nmethylurea (MNU). One week after the 5 weekly
cycles of MNU, the ratio of Ki67+ cells/Mist1+ cells was
increased in the stomachs of MNU-treated mice compared
to untreated controls, suggesting that MNU treatment
activates relatively quiescent Mist1+ cells (4% are Ki67+
at baseline) to become more proliferative (28% are Ki67+
after MNU) cells (Supplementary Figure 3A). In addition,
at 40 weeks MNU-derived tumors showed robust lineage
tracing from Mist1+ cells (Supplementary Figure 3B) in
50 % of mice analyzed (3/6), showing that MNU-induced
antral tumor is at least in part derived from Mist1+ cells.
We then crossed Mist1-CreERT mice with Apcflox/
flox
mice and generated Mist1-CreERT; Apcflox/flox mice in
order to examine the effect of Apc loss in Mist1+ cells.
As shown in Supplementary Figure 3C, 2 days after
TAM induction, there was strong nuclear translocation of
β-catenin evident in cells within the antral isthmus. The
number of cells positive for nuclear β-catenin increased
gradually, with small dysplastic nodules positive for
β-catenin widely present at 14 - 30 days after the TAM
induction. Apc-deleted Mist1+ lineages were initially
111014
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Figure 1: Mist1 marks long-lived, multipotent isthmus progenitors in the antrum. (A) Longitudinal stomach section of Mist1-

CreERT; R26-TdTomato mice stained with GS-II (green). Areas indicated by white boxes in the corpus and antrum are enlarged in right.
Macroscopic cut line of the section is shown by blue line in S1D. (B) In situ hybridization of Mist1 in the antrum. (C) Relative gene expression
per Gapdh in each part of the stomach (n = 3). (D–F) Lineage tracing in Mist1-CreERT; R26-mTmG mice from days 1-540. Arrows indicate
Mist1+ cells and their progeny. Quantification of the Mist1-traced cell position is shown in (E). A total of 50 glands were analyzed at each time
point. (G) Lineage tracing frequency in Mist1-CreERT; R26-mTmG, Mist1-CreERT; R26-TdTomato, and Mist1-CreERT; R26-LacZ mice
at day 1 and 360. (H) Immunofluorescence of the indicated markers (green) in Mist1-CreERT; R26-TdTomato mice 12 months after TAM
induction. (I) Antral gland culture of TAM-induced Mist1-CreERT; R26-mTmG mice. The arrow indicates Mist1+ cells.
www.impactjournals.com/oncotarget
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Figure 2: Mist1+ cells take up BrdU more rapidly than Lgr5+ cells. (A) Lgr5 (green) and Mist1 (red) expression in Mist1-CreERT;

Lgr5-DTR-GFP; R26-TdTomato mice 1 day after TAM induction. (B) FACS plot of Mist1-CreERT; Lgr5-DTR-GFP; R26-TdTomato mice
antrum 1 day after TAM induction. Boxes indicate Lgr5-low and Lgr5-high expressing cell populations. (C) Relative mRNA expression/
Gapdh of Lgr5 and Mist1 in Lgr5-high cells and Lgr5-low cells from the Mist1-CreERT; Lgr5-DTR-GFP; R26-TdTomato mice antrum 1
day after TAM induction. N.D. means “not detected”. N = 3. (D) Lineage tracing of DT-treated (day4 and day30 after tamoxifen induction)
Mist1-CreERT; Lgr5-DTR-GFP; R26-TdTomato mice. DT was given at 1 day after tamoxifen. (E) Immunofluorescence of GFP (green) and
BrdU (red) in Lgr5-EGFP-IRES-CreERT mice given BrdU continuously by drinking water (1.0 mg/ml). Mice were sacrificed at indicated
time points. (F) Immunofluorescence of GFP (green) and BrdU (red) in Mist1-CreERT; R26-mTmG mice given BrdU continuously by
drinking water. Mice were sacrificed at the indicated time points (1 day after TAM induction). (G) BrdU+ cell ratio of Lgr5+ cells and Mist1+
cells. A total of 300 cells from three mice were analyzed at each time point. (H) Antral images of Mist1-CreERT; R26-TdTomato mice
crossed to Cckbr-EGFP mice 1 and 180 days after TAM induction. Arrows indicate Tomato and EGFP double-positive cells. (I) FACS plot
of Mist1-CreERT; R26-TdTomato; Cckbr-EGFP mice 1 day after tamoxifen. (J–K) Immunofluorescence images showing CCK2R staining
(green) in Mist1-CreERT; R26-TdTomato mice 1 day and 14 days after TAM induction. CCK2R+ cells/Mist1+ cells are quantified in (K). A
total of 300 cells from three mice were analyzed. (L) Schematic model of antral stem/progenitor cells.
www.impactjournals.com/oncotarget
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Ki67-negative (day 7, 14), but later became Ki67+ after
the formation of large dysplasia (day 30 or after) (Figure
3D–3E). Sixty days after TAM induction, ten of 10 Mist1CreERT; Apcflox/flox mice (100 %) exhibited large antral
tumors, as shown previously in different Cre driver mice
[21] (Figure 3E, 3F). Notably, macroscopic tumors in
these mice are confined to the antrum (the incidence of
corpus tumor is 0 % (10/10)), while the normal corpus is
sometimes displaced proximally towards the forestomach
when the tumors enlarge at later stage. Although Mist1 is
also expressed in corpus stem cells and Brunner glands
in the duodenum, these tissues were unaffected by the
loss of Apc in Mist1+ cells. Thus, in the upper GI tract,
antral Mist1+ cells appeared uniquely susceptible to Apc/βcatenin-driven tumorigenesis.
Histologically, high-grade, intraepithelial neoplasia/
carcinoma in situ were seen in the antrum of Mist1CreERT; Apcflox/flox mice around 60 days after tamoxifen
induction, which expanded further by day 120 but
remained intra-mucosal without invasion (Supplementary
Figure 3D). Antral organoids of Mist1-CreERT; Apcflox/flox
mice can grow without Wnt3a and R-spondin 1 in culture
media only when recombination is induced by tamoxifen,
suggesting that the tumor development in these mice is
cell-autonomous effect (Supplementary Figure 3E, 3F).
The combination of Apc loss and Trp53 mutation led to
a higher dysplastic grade, compared to Apc loss alone,
but still remained intra-mucosal without invasion (Figure
3H). The addition of KrasG12D mutation to Apc loss led to
severe metaplasia and expansion of the neoplastic process
both in the antrum to the corpus, but again submucosal
invasion was not observed. The combination of Apc loss,
Kras mutation, and Trp53 mutation in Mist1 lineage also
generated dysplastic lesion resembling the tumors with
Apc knockout and Kras mutation both in the antrum and
corpus in 1 month, but all the mice died within a month
due to pancreatic tumor formation (not shown). Overall,
these findings indicate that Mist1+ cells can serve as an
origin of antral intestinal-type cancer.

of full mucosal layers (Figure 4B, 4C) [23]. Although
examination of a 5-μm section does not immediately
provide clear information of cell localization, 3D images
demonstrate that in the corpus, Cxcr4+ immune cells and
Cxcl12+ expression in the endothelium are predominantly
located in the isthmus region, and that in the antrum,
there are 2 distinct Cxcr4+ cells including basal epithelial
cells and immune cells throughout the mucosa, both
of which are surrounded by Cxcl12+ endothelial
network. Immunohistochemical staining confirmed that
Cxcl12+ cells were CD31+ endothelial cells, and not
podoplanin+ lymphatic cells nor α-SMA+ myofibroblasts
(Supplementary Figure 4B).
Cxcr4+ antral epithelial cells can exist in cultured
organoids, with a gradual expansion during the time course
(Figure 4D). We utilized Mist1-CreERT; R26-TdTomato;
Cxcr4-EGFP mice to investigate possible overlap between
Cxcr4+ and Mist1+ epithelial cells. Two days after TAM
induction, the Tomato signal (Mist1+ cell) and the GFP
signal (Cxcr4+ cells) were found to overlap in isolated cells
near the +5 position (Figure 4E). On day 14 after TAM
induction, most of the Cxcr4+ cells were clearly derived
from the Mist1+ progeny. FACS analysis of antral cells
from Mist1-CreERT; R26-TdTomato; Cxcr4-EGFP mice
confirmed the presence of double-positive (Mist1+Cxcr4+)
cells (Figure 4F), while there was no double-positive cells
in the corpus [9]. Single cell culture analysis revealed that
Mist1+Cxcr4+ double-positive cells showed a higher rate of
colony formation compared to single-positive or doublenegative populations (Figure 4G–4H).
Approximately 50% of Cxcr4-EGFP+ cells
expressed Ki67 in the lower half of glands, and thus
presumably included many of the active stem/progenitor
cells in this region such as Lgr5+ cells (Figure 4I).
Interestingly, CCK2R+ stem cells in the antrum were
negative for Cxcr4-EGFP (Figure 4J–4K). Some of the
gastrin-expressing (G) cells also expressed Cxcr4-EGFP,
whereas there was no overlap at baseline between Cxcr4EGFP and Dclk1+ tuft cells or somatostatin+ D-cells (not
shown). We found that Cxcr4+CD45+ immune cells present
in the antrum were primarily Lin-CD90.2+Cxcr4+ ILCs
(Supplementary Figure 4C-4D). Thus, these data indicate
that that Mist1+ antral progenitors are localized within the
Cxcl12/Cxcr4 perivascular niche.

Cxcl12/Cxcr4 axis contributes to antral stem cell
niche
We previously showed that the Cxcl12+
endothelium and Cxcr4+ ILCs regulated gastric corpus
stem cells and also contributed strongly to diffuse-type
gastric cancer development [9]. When we observed
Cxcl12/Cxcr4 expression in the entire stomach of Cxcl12dsRED; Cxcr4-GFP mice, Cxcr4+ epithelial cells were
abundant at the lower half of the antral glands (positions
1-10), while Cxcr4+ epithelial cells were absent and
instead rare Cxcr4+ immune cells is present in the corpus
as previously reported [9, 22] (Supplementary Figure
4A). In order to visualize distinct expression pattern
between these two parts more clearly, we utilized tissue
decolorization method and performed 3D reconstitution
www.impactjournals.com/oncotarget

Cxcl12/Cxcr4 axis contributes to antral tumor
growth
We next investigated the contribution of the
Cxcl12/Cxcr4 axis to antral gastric tumorigenesis using
two different mouse models: conditional Apc knockout
in Mist1+ cells and MNU-induced antral tumorigenesis.
While Cxcr4+ epithelial cells are normally at the gland
base surrounded by Cxcl12+ endothelial cells, there was
marked expansion of Cxcr4+ epithelial cells to within the
antral tumor (Figure 5A–5D). Cxcr4 gene expression is
111017

Oncotarget

Cxcl12flox/flox mice (control littermates) was comparable
(Supplementary Figure 5A). However, while MNU
treatment caused marked proliferation (increased Ki67+
cells) and expansion of Cxcr4+ epithelial cells in control
mice, MNU-treated Tie2-Cre; Cxcr4-EGFP; Cxcl12flox/flox
mice showed much smaller changes, with significantly
decreased Cxcr4+ epithelial cells and Ki67+ cells compared
to MNU treated controls (Figure 5F).
To assess the contribution of Cxcr4+ ILCs in antral
tumor development, we treated MNU-treated mice with
an anti-CD90.2 antibody. While treatment with the antiCD90.2 antibody efficiently depleted CD90.2+ ILCs,
MNU-induced tumor development was not inhibited in
this protocol (Supplementary Figure 5B–5D). Thus, these
data suggest that the expansion of the Cxcl12+ endothelium

upregulated in tumors than in normal antrum. In addition,
there was a corresponding expansion of Cxcl12+ stromal
cells. Tissue decolorization and 3D reconstitution
successfully emphasized remarkable expansion of Cxcl12/
Cxcr4 expressing cells within antral tumor (Figure 5E).
Interestingly, there are strong Cxcr4-GFP expressing
clusters within the tumor, suggesting the clonal expansion
of Cxcr4+ cells in dysplastic glands.
To elucidate the functional role of the Cxcl12/
Cxcr4 axis in antral tumorigenesis, we generated Tie2Cre; Cxcl12flox/flox mice with targeted deletion of Cxcl12
in endothelial cells, and used these animals in the MNU
tumor model. In untreated mice at baseline, the expression
of Cxcr4 and Ki67 in antral epithelial cells of Tie2-Cre;
Cxcr4-EGFP; Cxcl12flox/flox mice and Cxcr4-EGFP;

Figure 3: Antral Mist1+ cells serve as a cellular origin of cancer. (A) Alcian blue (blue) staining in Mist1-CreERT; LSL-KrasG12D

mice at the indicated time points. (B) GSII (green) and CD44 (red) staining in Mist1-CreERT; LSL-KrasG12D mice at the indicated time points.
(C) CD44 (green) and p-ERK (red) staining in Mist1-CreERT; LSL-KrasG12D mice at day 30 after tamoxifen. (D-E) Immunofluorescence for
β-catenin (green) and Ki67 (red) in Mist1-CreERT; Apcflox/flox mice on days 7, 30, and 60 after TAM induction (D). The arrows indicate the
nuclear β-catenin+ cells. Ki67+ cell ratio in total nuclear β-catenin+ cells is quantified (E). A total of 300 cells from three mice are analyzed
at each time point. (F) Longitudinal H&E stained section of Mist1-CreERT; Apcflox/flox mouse stomach 60 days after TAM induction. (G)
Gross picture Mist1-CreERT; Apcflox/flox mice 60 and 90 days after TAM induction. (H) H&E staining of Mist1-CreERT; LSL-Trp53R172H;
Apcflox/flox mice and Mist1-CreERT; LSL-KrasG12D; Apcflox/flox mice 150 days after TAM induction.
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endothelium downregulated gene expression of Cxcr4
as well as Mist1, while Cckbr was upregulated in Tie2Cre; Cxcl12flox/flox mice compared to control mice (Figure
5H). Lgr5 gene expression was not altered by conditional
Cxcl12 knockout. These results suggest that knockout
of Cxcl12 in the endothelium inhibited expansion of the
Mist1+Cxcr4+ cell population, but the loss of Mist1+ cells

may contribute to antral tumorigenesis in this model
predominantly through activation of Cxcr4+ epithelial
stem/progenitors, rather than through regulation of ILCs.
The macroscopic tumor size was significantly
smaller in the MNU-treated Tie2-Cre; Cxcr4-EGFP;
Cxcl12flox/flox mice compared to controls (Figure 5G).
RT-PCR analysis revealed that deletion of Cxcl12 in the

Figure 4: Cxcl12/Cxcr4 axis contributes to antral stem cell niche. (A) Longitudinal stomach section of Cxcr4-EGFP; Cxcl12-

dsRED mice stained with DAPI. Areas indicated by white boxes in the corpus and antrum are enlarged in right. (B) Representative gross
images of control and decolorized stomachs. (C) 3D reconstructed images of Cxcr4-EGFP; Cxcl12-dsRED mouse corpus and antrum
stained with DAPI. (D) Antral gland culture of Cxcr4-EGFP; R26-mTmG mice. (E) Lineage tracing of Mist1-CreERT; R26-TdTomato;
Cxcr4-EGFP mice 2 and 14 days after TAM induction. Arrow indicates double positive cells. (F) FACS plot of antral cells from Mist1CreERT; Cxcr4-EGFP; R26-TdTomato mice 1 day after TAM induction. Representative images of each cellular population are shown.
(G-H) Single cell culture images (G) and relative colony formation efficacy of sorted cells (H). Double-negative cells, Cxcr4+ cells (green),
Mist1+ cells (red), and double-positive cells (yellow) were analyzed. (I–K) Immunofluorescence staining of Ki67 and gastrin (I, red), and
CCK2R (J, red) in Cxcr4-EGFP mice. Ki67+, Gastrin+, and CCK2R+ cell ratio in Cxcr4+ cells are quantified in (K). A total of 300 cells from
three mice were analyzed.
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Figure 5: Cxcl12/Cxcr4 axis contributes to antral tumor growth. (A) Longitudinal stomach section of Mist1-CreERT; Apcflox/

; Cxcr4-EGFP; Cxcl12-dsRED mice 60 days after tamoxifen stained with DAPI. Arrows indicate dysplastic lesions. (B) Relative gene
expression per Gapdh in normal antrum and antral tumors of Mist1-CreERT; Apcflox/flox mice 60 days after tamoxifen. (C–D) Cxcl12-dsRED;
Cxcr4-EGFP mouse antrum without (control antrum) and after MNU treatment (MNU-treated), and Mist1-CreERT; Cxcl12-dsRED; Cxcr4EGFP; Apcflox/flox mice 6 weeks after TAM induction (Apcflox/flox). Cxcl12+ and Cxcr4+ areas were measured in (D). A total of 30 high power
fields (HPF) from three mice were analyzed. (E) 3D reconstructed images of Mist1-CreERT; Apcflox/flox; Cxcr4-EGFP; Cxcl12-dsRED mouse
antrum 60 days after tamoxifen stained with DAPI. (F) GFP and Ki67 staining of Cxcr4-EGFP; Cxcl12flox/flox (control) mice and Tie2-Cre;
Cxcr4-EGFP; Cxcl12flox/flox mice 40 weeks after the start of 5 cycles of MNU treatment. Cxcr4+ and Ki67+ epithelial cell ratio of Cxcr4EGFP; Cxcl12flox/flox (control) mice and Tie2-Cre; Cxcr4-EGFP; Cxcl12flox/flox mice were quantified. The total 1500 cells from three mice
are analyzed. (G) Macroscopic antral tumor size was measured in Cxcl12flox/flox (control, N = 13) mice and Tie2-Cre; Cxcl12flox/flox mice (N
= 7) 40 weeks after the start of 5 cycles of MNU treatment. (H) Relative mRNA expression/Gapdh of the indicated genes from the MNUinduced tumor tissues in Cxcl12flox/flox mice (Ctr) and Tie2-Cre; Cxcl12flox/flox mice (Tie2).
flox
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in the antrum with loss of Apc [21]. The enhancer
element eR1 is recently reported corpus/antral stem and
progenitor cell marker [13], but the expression is scattered
and its biology and contribution to cancers are not fully
determined. Axin2 is also expressed in both broad isthmus
progenitor cells and basal Lgr5+ cells, and likely overlaps
with eR1 or other markers. Finally, CCK2R+ antral stem
cells which were identified by our group [12] reside at +4
position and appear to show quite close proximity to Mist1+
antral cells. Our current findings using fluorescent imaging
and FACS analysis failed to demonstrate the evident
overlap between Mist1 and other markers. Nonetheless, we
do not exclude the possibility that some of reported stem/
progenitor cell markers (e.g., eR1, Sox2, or Axin2) may
contain Mist1+ cells when using reported CreERT lines. It
should be noted that Mist1 expression is more restricted
to the isthmus region than other markers, however, it
may be possible that Mist1 marks heterogeneous isthmus
progenitors that are long-lived.
We show here that Mist1+ cells can serve as the
cell-of-origin for antral gastric tumors. It has long been
suspected that cancer arises from genetic alterations in
stem cells, given their longevity and capacity for selfrenewal [26]. Indeed, Lgr5+ and Sox2+ cells can also
give rise to dysplasia or tumors with loss of the Apc gene
[10, 21]. We have shown here that relatively quiescent
Mist1+ cells can give rise to cancer after exposure to the
carcinogen (MNU) or loss of Apc. In the distal stomach,
intestinal-type gastric cancer is the more common
histologic type, and is typically associated with activation
of the Wnt/β-catenin signaling pathway [10, 27]. Indeed,
the frequency of Apc mutation in human intestinal-type
gastric cancer is significantly higher than that in diffusetype [28]. The fact that Apc mutation models in the
stomach resulted only in antral tumors without corpus
tumor may suggest that the susceptibility to cancer in
response to certain oncogenes and carcinogens is different
between the antrum and corpus. In humans, MSI+ cancers
are more common in antral cancers, while Tp53-mutated
CIN+ tumors are found more often in proximal cancers.
Thus, it may be crucial to understand the molecular
mechanism in both antral and corpus carcinogenesis
separately.
In previous studies, we found that the development
of diffuse-type corpus cancer was highly dependent on an
endothelial niche, with Cxcl12 signaling from endothelial
cells to Cxcr4-expressing ILCs, which then activate Mist1+
corpus stem cells through Wnt5a secretion. In the current
study, we observed a similar juxtaposition of Cxcl12expressing endothelial cells adjacent to Mist1+ antral cells.
In addition, we previously reported that Cxcl12/Cxcr4
signaling is involved in activation and recruitment of
cancer-associated fibroblasts during gastric carcinogenesis,
and that aberrant expression of Cxcl12 accelerates gastric
cancer development [22, 29]. Here, we show clear Cxcr4
expression in the Mist1+ antral cells, and in response to

may have been partially compensated by CCK2R+ stem
cell expansion.

Pharmacological blockade of Cxcr4 inhibits
antral tumor growth
Finally, to test the possible therapeutic utility of
pharmacologic inhibition of the Cxcl12/Cxcr4 axis on
antral tumor development, we treated Mist1-CreERT;
Cxcr4-EGFP; Apcflox/flox mice with AMD3100, a specific
inhibitor of CXCR4. AMD3100 significantly reduced the
number of Cxcr4+ epithelial cells in the gastric antrum
and decreased macroscopic tumor size (Figure 6A–6C).
In the Mist1-CreERT; Apcflox/flox mice, most dysplastic cells
demonstrated nuclear translocation of β-catenin. However,
CCK2R+ cells in these murine tumors did not show nuclear
expression of β-catenin (Figure 6D). Thus, the majority of
Apc-deleted Mist1+ cells do not interconvert to CCK2R+
cells during this rapid tumor formation. Furthermore, the
numbers of CCK2R+ cells were increased when mice were
treated with AMD-3100 (Figure 6E), suggesting again that
in this tumorigenic setting, CCK2R+ cells may behave as a
compensatory lineage, distinct from Mist1+ cells.

DISCUSSION
In the current study, we identified Mist1+ long-lived
progenitor cells in the gastric antrum that are distinct from
other reported gastric stem cell populations, including
Lgr5+ cells and CCK2R+ cells. In addition, we have
shown that antral Mist1+ cells can serve as an origin of
gastric tumors in a different way from the corpus Mist1+
stem cells. Mist1+ progenitors overlap in the antrum with
Cxcr4+ antral stem/progenitor cells, which appear to be
supported by Cxcl12 secreted from endothelial cells
within a perivascular niche. Activation of Cxcl12/Cxcr4
signaling appears to be needed for antral tumor growth.
Earlier studies using electron microscopy and
autoradiography suggested that antral stem cells with an
undifferentiated, granule-free appearance reside within the
isthmus, and supply daughter cells bidirectionally towards
the top and the base of the glands [24, 25]. Several markers
have been reported for actively cycling antral stem cells,
but until now clear relationship between these markers has
not been well established [10–12]. In the paper describing
Villin+ progenitors [14], the authors used Villin-LacZ and
Villin-Cre mice and found rare Villin+ cells in the isthmus
of antral glands which can show traced glands only when
mice are treated with interferon (INF). The phenotype
of INF-dependent tracing definitely suggests that Villin+
cells are not stem or progenitor cells in normal state and
distinct from Mist1+ cells. Sox2 was initially reported to be
expressed in rare stem cells within the corpus and antrum
isthmus in the adult stomach [11]. More recently Sox2 was
found to be expressed in broader transit-amplifying cells in
the antral isthmus, which contribute to tumor development
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carcinogen exposure, there was a marked expansion of
Cxcr4+ epithelial cells that eventually encompassed almost
the entire gland. Thus, Cxcr4 signal may broadly affect
gastric carcinogenesis through multiple mechanisms.
Interestingly, while Cxcr4 inhibition leads to
suppression of Mist1-derived tumor growth, there is
compensatory activation of the CCK2R lineage, which we
showed was negative for Cxcr4 expression. Thus, in the
absence of Cxcl12/Cxcr4 signaling and reduction in the
Mist1 lineage, there is an upregulation of CCK2R+ cells (but
interestingly not Lgr5+ cells), suggesting that other stem cell
populations can compensate for loss of the Mist1 lineage.
Given this observation, it may be interesting to consider
simultaneous blockade of the Cxcr4 axis and inhibition of
CCK2R+ cells may achieve better tumor suppression.
MIST1 expression in human gastric antrum was
recently described [30], and epithelial Cxcr4 expression
in human gastric cancer tissue has been also reported
[31, 32]. In addition, a meta-analysis reported that Cxcr4
expression in primary human gastric cancer tissues was
positively associated with tumor progression and disease

prognosis, including vascular invasion [33]. Thus, we
believe that Cxcr4+ epithelial cells, which include the
Mist1+ antral progenitors, contribute to human gastric
cancer progression, and that the Cxcr4/Cxcl12 axis
may still be a promising therapeutic target against
broad spectrum of gastric cancers. While targeting the
endothelium using antibodies to vascular endothelial
growth factor receptor 2 (VEGFR-2) has shown benefit in
some tumors in clinical trials [34, 35], the role of Cxcl12
secretion in the response has not been explored. The
current study provides further support for the existence
of Cxcl12 endothelium as a representing key niche for
gastrointestinal stem cells.

MATERIALS AND METHODS
Mice
Mist1-CreERT mice [36] and Cxcl12-dsRED mice
[37] were described previously. Cxcr4-EGFP mice were
provided from Richard J. Miller (North-western University

Figure 6: Pharmacological blockade of Cxcr4 inhibits antral tumor growth. (A–C) Gross picture (A, top) and

immunofluorescence images (A, bottom) of GFP (green) and Ki67 (red) in Mist1-CreERT; Cxcr4-EGFP; Apcflox/flox mice 6 weeks after
TAM induction with or without 2 weeks AMD3100 treatment. The dashed-line indicates tumor area. Macroscopic antral tumor area was
quantified in (B) (N = 4 /group). The percentage of Cxcr4+ epithelial cells per total Ki67+ cells was quantified in (C). A total of 1500 cells
from three mice were analyzed. (D) H&E staining and immunofluorescence of CCK2R (green) and β-catenin (red) in Mist1-CreERT2;
Apcflox/flox mice 6 weeks after TAM induction. (E) Immunofluorescence of GFP (green) and CCK2R (red) in Mist1-CreERT2; Apcflox/flox mice
6 weeks after TAM induction with or without AMD3100 treatment. CCK2R+ cells/gland were counted. A total 150 glands from three mice
were analyzed.
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